Business · 24/10/20261 min read
The following information is provided for in the Annex to Regulation (EU) No 575/2013:
Summary
The Food and Drug Administration (FDA) is announcing the issuance of a priority review voucher to the sponsor of a rare pediatric disease product application.
Original source language: Federal Register — Health and Human ServicesOpen original release →